John D. Stratigis

John D. Stratigis

Auto-generated profile, based on publicly available information

John D. Stratigis

Division of General, Thoracic and Fetal Surgery, Center for Fetal Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2019 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
DADeepthi Alapati
Deepthi Alapati
WZWilliam J. Zacharias
William J. Zacharias
HHHeather A. Hartman
Heather A. Hartman
ARAvery C. Rossidis
Avery C. Rossidis
JSJohn D. Stratigis
John D. Stratigis
WPWilliam H. Peranteau
William H. Peranteau
Monogenic lung diseases that are caused by mutations in surfactant genes of the pulmonary epithelium are marked by perinatal lethal respiratory failure or chronic diffuse parenchymal lung disease with few therapeutic options. Using a CRISPR fluorescent reporter system, we demonstrate that precisely timed in utero intra-amniotic delivery of CRISPR-Cas9 gene editing reagents during fetal development results in targeted and specific gene editing in fetal lungs. Pulmonary epithelial cells are predominantly targeted in this approach, with alveolar type 1, alveolar type 2, and airway secretory cells exhibiting high and persistent gene editing. We then used this in utero technique to evaluate a therapeutic approach to reduce the severity of the lethal interstitial lung disease observed in a mouse model of the human SFTPCI73T mutation. Embryonic expression of SftpcI73T alleles is characterized by severe diffuse parenchymal lung damage and rapid demise of mutant mice at birth. After in utero CRISPR-Cas9–mediated inactivation of the mutant SftpcI73T gene, fetuses and postnatal mice showed improved lung morphology and increased survival. These proof-of-concept studies demonstrate that in utero gene editing is a promising approach for treatment and rescue of monogenic lung diseases that are lethal at birth.

9 September 2023 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
SBSourav K. Bose
Sourav K. Bose
JSJohn D. Stratigis
John D. Stratigis
NANicholas Ahn
Nicholas Ahn
JPJennifer Pogoriler
Jennifer Pogoriler
HHHolly L. Hedrick
Holly L. Hedrick
WPWilliam H. Peranteau
William H. Peranteau

1 September 2018 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
JRJohn S. Riley
John S. Riley
LMLauren E McClain
Lauren E McClain
JSJohn D. Stratigis
John D. Stratigis
BCBarbara E Coons
Barbara E Coons
HLHaiying Li
Haiying Li
WPWilliam H. Peranteau
William H. Peranteau
In utero hematopoietic cell transplantation (IUHCT) is a nonmyeloablative nonimmunosuppressive alternative to postnatal hematopoietic stem cell transplantation for the treatment of congenital hemoglobinopathies. Anti-HLA donor-specific Abs (DSA) are associated with a high incidence of graft rejection following postnatal hematopoietic stem cell transplantation. We determine if DSA present in the mother can similarly cause graft rejection in the fetus following IUHCT. Ten million C57BL/6 (B6, H2kb) bone marrow cells were transplanted in utero into gestational day 14 BALB/c (H2kd) fetuses. The pregnant BALB/c dams carrying these fetuses either had been previously sensitized to B6 Ag or were injected on gestational days 13–15 with serum from B6-sensitized BALB/c females. Maternal–fetal Ab transmission, Ab opsonization of donor cells, chimerism, and frequency of macrochimeric engraftment (chimerism >1%) were assessed by flow cytometry. Maternal IgG was transmitted to the fetus and rapidly opsonized donor cells following IUHCT. Donor cell rejection was observed as early as 4 h after IUHCT in B6-sensitized dams and 24 h after IUHCT in dams injected with B6-sensitized serum. Efficient opsonization was strongly correlated with decreased chimerism. No IUHCT recipients born to B6-sensitized dams or dams injected with B6-sensitized serum demonstrated macrochimeric engraftment at birth compared with 100% of IUHCT recipients born to naive dams or dams injected with naive serum (p < 0.001). In summary, maternal donor–specific IgG causes rapid, complete graft rejection in the fetus following IUHCT. When a third-party donor must be used for clinical IUHCT, the maternal serum should be screened for DSA to optimize the chance for successful engraftment.

16 December 2022 in Experimental Hematology
Verified
Journal Article
Closed access
JRJohn S. Riley
John S. Riley
LMLauren E. McClain
Lauren E. McClain
JSJohn D. Stratigis
John D. Stratigis
BCBarbara E. Coons
Barbara E. Coons
SBSourav K. Bose
Sourav K. Bose
WPWilliam H. Peranteau
William H. Peranteau

16 February 2026 in Journal of Pediatric Surgery Case Reports
Verified
Journal Article
Open access
ACAshley Carducci
Ashley Carducci
MRMarina L. Reppucci
Marina L. Reppucci
NBNaina Bagrodia
Naina Bagrodia
SBSamuel Bitton
Samuel Bitton
JSJohn D. Stratigis
John D. Stratigis